© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Oddbjørn Straume, MD, PhD, associate professor, department of Clinical Science, Haukeland University Hospital, discusses a study investigating BGB324 with pembrolizumab or dabrafenib/trametinib in patients with advanced non-resectable or metastatic melanoma.